A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
|Articles|July 26, 2021
Pharmacy Times: Week of July 26 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Theresa McArdle, the senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.
- A new episode of the Pharmacy Focus podcast featuring Pamela Spicer, MS, who will be discussing new data surrounding the approval of aducanumab for Alzheimer disease.
- An article that discusses the 5 key things pharmacists need to know as insulin biosimilars come to market.
- A pharmacy quiz on treatments for diabetes.
Advertisement
Related to this article
As pharmaceutical markets become increasingly dynamic, health systems may benefit from shifting toward unit-level economic frameworks that evaluate cost and margin performance.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5